ChristineNicholsKayMD
Ophthalmology • Gainesville, FLRetinal Disease
Assistant Professor, Ophthalmology, University of Florida College of
Are you Dr. Kay?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4340 Newberry Rd
Ste 202
Gainesville, FL 32607Phone+1 352-371-2800Fax+1 352-378-7009
Summary
- Dr. Christine Kay, MD is a board certified ophthalmologist in Gainesville, Florida. She is currently licensed to practice medicine in Florida and Iowa. She is an Assistant Professor at University of Florida College of.
Education & Training
University of Florida College of MedicineClass of 2005
Certifications & Licensure
FL State Medical License 2007 - 2026
IA State Medical License 2009 - 2011
American Board of Ophthalmology Ophthalmology
Publications & Presentations
PubMed
- 1 citationsEndpoints and Design for Clinical Trials in USH2A-Related Retinal Degeneration: Results and Recommendations From the RUSH2A Natural History Study.Maureen G Maguire, David G Birch, Jacque L Duncan, Allison R Ayala, Lauren N Ayton
Translational Vision Science & Technology. 2024-10-01 - 7 citationsSafety and efficacy of ATSN-101 in patients with Leber congenital amaurosis caused by biallelic mutations in GUCY2D: a phase 1/2, multicentre, open-label, unilateral d...Paul Yang, Laura P Pardon, Allen C Ho, Andreas K Lauer, Dan Yoon
Lancet. 2024-09-07 - 10 citationsAssessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2/3 Study.Byron L Lam, Mark E Pennesi, Christine N Kay, Sushil Panda, James A Gow
Ophthalmology. 2024-09-01
Press Mentions
Alkeus Secures Rare Pediatric Disease and Fast Track FDA Designations for Gildeuretinol in Stargardt DiseaseNovember 19th, 2024- Atsena Therapeutics Announces Positive 6-Month Data from Ongoing Phase I/II Clinical Trial of ATSN-101 in Patients with Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (LCA1)April 25th, 2023
- Atsena Therapeutics Announces Positive Results from Phase I/II Clinical Trial of ATSN-101 for the Treatment of GUCY2D-Associated Leber Congenital Amaurosis (LCA1)October 3rd, 2022
- Join now to see all
